Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B), while ProShares UltraPro S&P500 trades at $155 (market cap $5.57B). The key difference: ProShares UltraPro S&P500 is far larger — about 2.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| SLS | UPRO | |
|---|---|---|
Market Cap | $2.28B | $5.57B |
Volume | 3,128,960 | 1,824,096 |
Sector | Health | Leveraged / Inverse |
52-Week High | $15.46 | $157.66 |
52-Week Low | $1.39 | $89.29 |
Enterprise Value | $2.15B | — |
Typical Hold Time | — | 29 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.21, down 0.77% on the day, while maintaining a bullish technical stance with strong moving average support. The stock shows neutral momentum oscillators but benefits from positive market sentiment around S&P 500 exposure. Recent news highlights strong corporate earnings growth expectations of 35% for 2026, though concerns exist about concentration risks in top holdings and potential profit growth slowdown to 15% in 2027.
The outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and AI-driven earnings growth, though investors face risks from market concentration, elevated valuations, and potential Federal Reserve policy impacts. Wall Street expects continued gains but acknowledges the need for selective positioning amid changing market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
